{"analyses":[{"ciLowerLimit":"0.38","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.58","estimateComment":"Reference arm = Chemotherapy","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.48","pValueComment":"Two-sided significance level = 0.05","paramType":"Hazard Ratio (HR)","paramValue":"0.77","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"The median has not yet been reached. Additionally there were not enough events to estimate the upper confidence boundary.","groupId":"OG000","lowerLimit":"2.6","upperLimit":"NA","value":"NA"},{"comment":"The median has not yet been reached. Additionally there were not enough events to estimate the upper confidence boundary.","groupId":"OG001","lowerLimit":"4.5","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"description":"Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Rituximab, methotrexate, procarbazine for four 28-day cycles with vincristine for the first two cycles, followed 3-5 weeks later by two 28-day cycles of cytarabine.","id":"OG000","title":"Chemotherapy"},{"description":"Rituximab, methotrexate, procarbazine for four 28-day cycles with vincristine for the first two cycles, followed 2-5 weeks later by 3 weeks of low-dose whole-brain radiotherapy (WBRT), followed 3-5 weeks later by two 28-day cycles of cytarabine.","id":"OG001","title":"Chemotherapy + Low-Dose WBRT"}],"paramType":"MEDIAN","populationDescription":"Eligible participants","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up. Maximum follow-up at time of analysis was 7.3 years.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"years"}